Buy Rating Affirmed: AIM ImmunoTech's Ampligen Shows Promising Oncology Pipeline Progress
Analysts Offer Insights on Healthcare Companies: AIM ImmunoTech (AIM) and Avid Bioservices (CDMO)
Buy Rating Affirmed for AIM ImmunoTech Amidst Promising Trials and Product Pipeline Developments
Strong Financial Position and Promising Clinical Trials Bolster Buy Rating for AIM ImmunoTech: An Analysis by Jason McCarthy
Analysts Are Bullish on These Healthcare Stocks: AIM ImmunoTech (AIM), Microbot Medical (MBOT)
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and AIM ImmunoTech (AIM)
Ascendiant Remains a Buy on AIM ImmunoTech (AIM)
Maxim Group Sticks to Their Buy Rating for AIM ImmunoTech (AIM)
AIM ImmunoTech (AIM) Receives a Buy From Maxim Group
Maxim Group Keeps Their Buy Rating on AIM ImmunoTech (AIM)
Maxim Group Sticks to Its Buy Rating for AIM ImmunoTech (AIM)
No Data